Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires Shares of 15,237 Globus Medical, Inc. $GMED

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Globus Medical, Inc. (NYSE:GMED) during the fourth quarter, Holdings Channel.com reports. The fund purchased 15,237 shares of the medical device company’s stock, valued at approximately $1,330,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. raised its position in shares of Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Globus Medical during the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Larson Financial Group LLC raised its position in shares of Globus Medical by 83.4% during the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after purchasing an additional 242 shares during the period. Finally, Parallel Advisors LLC raised its position in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 18.38% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GMED. Royal Bank Of Canada increased their price target on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Wells Fargo & Company dropped their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Finally, Barclays increased their price target on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Price Performance

Shares of GMED stock opened at $84.46 on Friday. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market capitalization of $11.46 billion, a price-to-earnings ratio of 19.64, a price-to-earnings-growth ratio of 1.73 and a beta of 1.00. The business has a 50 day simple moving average of $87.31 and a 200 day simple moving average of $87.83.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period in the prior year, the company posted $0.68 EPS. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.